Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:37 pm Sale | 2024-09-30 | 13G | Mirum Pharmaceuticals, Inc. MIRM | BIOTECHNOLOGY VALUE FUND L P | 3,075,907 6.400% | -1,294,117 (-29.61%) | Filing History |
| 2024-11-14 4:36 pm Purchase | 2024-09-30 | 13G | Annexon, Inc. ANNX | BIOTECHNOLOGY VALUE FUND L P | 9,027,778 8.400% | 2,027,778 (+28.97%) | Filing History |
| 2024-11-14 4:36 pm Purchase | 2024-09-30 | 13G | AC Immune S.A. ACIU | BIOTECHNOLOGY VALUE FUND L P | 19,522,436 19.700% | 4,951,200 (+33.98%) | Filing History |
| 2024-11-14 4:34 pm Purchase | 2024-09-30 | 13G | Tyra Biosciences, Inc. TYRA | BIOTECHNOLOGY VALUE FUND L P | 4,661,194 8.800% | 1,921,599 (+70.14%) | Filing History |
| 2024-11-14 4:33 pm Sale | 2024-09-30 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,833,785 (Position Closed) | Filing History |
| 2024-11-14 4:32 pm Sale | 2024-09-30 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 4,212,346 5.400% | -3,160,882 (-42.87%) | Filing History |
| 2024-11-14 4:32 pm Purchase | 2024-09-30 | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 883,844 1.300% | 883,844 (New Position) | Filing History |
| 2024-11-14 4:30 pm Sale | 2024-09-30 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,347,946 (Position Closed) | Filing History |
| 2024-11-14 4:30 pm Sale | 2024-09-30 | 13G | 89bio, Inc. ETNB | BIOTECHNOLOGY VALUE FUND L P | 6,811,631 6.400% | -756,849 (-10.00%) | Filing History |
| 2024-11-14 4:29 pm Sale | 2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -1,563,963 (Position Closed) | Filing History |
| 2024-11-14 4:29 pm Purchase | 2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY | BIOTECHNOLOGY VALUE FUND L P | 1,047,123 9.990% | 700,101 (+201.74%) | Filing History |
| 2024-11-14 4:28 pm Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 6,230,845 9.990% | 1,779,960 (+39.99%) | Filing History |
| 2024-11-14 4:27 pm Sale | 2024-09-30 | 13G | Protagonist Therapeutics, Inc. PTGX | BIOTECHNOLOGY VALUE FUND L P | 2,970,427 4.900% | -2,793,521 (-48.47%) | Filing History |
| 2024-11-14 4:27 pm Purchase | 2024-09-30 | 13G | Zymeworks Inc. ZYME | BIOTECHNOLOGY VALUE FUND L P | 4,607,935 6.500% | 4,607,935 (New Position) | Filing History |
| 2024-11-14 4:26 pm Purchase | 2024-09-30 | 13G | CytomX Therapeutics, Inc. CTMX | BIOTECHNOLOGY VALUE FUND L P | 8,089,795 9.990% | 1,386,906 (+20.69%) | Filing History |
| 2024-11-14 4:26 pm Sale | 2024-09-30 | 13G | Lexicon Pharmaceuticals, Inc. LXRX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -24,435,632 (Position Closed) | Filing History |
| 2024-11-14 4:24 pm Purchase | 2024-09-30 | 13G | Cullinan Oncology, Inc. CGEM | BIOTECHNOLOGY VALUE FUND L P | 5,796,433 9.990% | 1,403,112 (+31.94%) | Filing History |
| 2024-11-14 4:24 pm Sale | 2024-09-30 | 13G | Janux Therapeutics, Inc. JANX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -4,579,818 (Position Closed) | Filing History |
| 2024-11-14 4:23 pm Sale | 2024-09-30 | 13G | IDEAYA Biosciences, Inc. IDYA | BIOTECHNOLOGY VALUE FUND L P | 1,409,993 1.700% | -2,069,050 (-59.47%) | Filing History |
| 2024-11-14 4:22 pm Purchase | 2024-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 703,126 9.990% | 703,126 (New Position) | Filing History |